Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$48.8MCash on Hand
15.5mo Cash Runway
Follow ATYR by emailGet an email when ATYR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ATYR, unsubscribe in one click. Privacy
📣 What ATYR Says Is Next
second quarter of 2027 · Efzofitimod: “Full study results are expected in the second quarter of 2027.”
Company press release, Nov 5, 2026 · SEC filing
fourth quarter of 2026 · “The Company expects to focus on regulatory submissions in the U.S. and Europe as it initiates study-related activities in the fourth quarter of 2026.”
Company press release, Sep 24, 2026 · SEC filing
first quarter of 2027 · “Topline results are expected in the first quarter of 2027.”
Company press release, Aug 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Listing aTyr Pharma regained compliance with Nasdaq's $1.00 minimum bid price rule after its closing bid stayed at or above $1.00 for 10 consecutive business days, from October 30 to November 12, 2026. The company has no outstanding Nasdaq deficiency notices. Form 8-K · SEC filing
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Financing aTyr Pharma filed a prospectus supplement for an at-the-market offering of up to $79,994,251 of common stock through Jefferies, with a commission of up to 3.0%. The amount remains unsold under the prior agreement, and the stock closed at $6.03 on November 5, 2026. Form 424B5 · SEC filing
Nov 6, 2026 ·
Financing Filed a prospectus supplement for an at-the-market sale of common stock with Jefferies LLC, allowing offerings of up to $79,994,251 under an existing shelf registration effective August 18, 2025. Form 8-K · SEC filing
Nov 5, 2026 ·
Earnings aTyr reported Q3 2026 cash of $50.3 million, with runway into late 2028, and R&D expenses of $10.4 million and G&A of $8.3 million. It reached FDA alignment on a Phase 3 efzofitimod protocol in pulmonary sarcoidosis and is prioritizing strategic partnerships to advance it. Form 8-K · SEC filing · Press release
Oct 27, 2026 ·
Listing aTyr Pharma filed a Certificate of Amendment to effect a 1-for-40 reverse stock split, effective 5:00 p.m. ET on October 28, 2026. Shares outstanding fall from about 100.5 million to about 2.5 million, and trading resumes split-adjusted on Nasdaq under ATYR on October 29, 2026. Form 8-K · SEC filing
Oct 16, 2026 ·
Shareholder vote Stockholders approved a proposal giving the Board discretion to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50. The vote was 52,451,734 for, 5,234,645 against and 228,991 abstaining, with 59.04% of outstanding shares represented. Form 8-K · SEC filing
Sep 24, 2026 ·
Regulatory Reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in chronic symptomatic pulmonary sarcoidosis with restrictive lung disease. The 54-week, randomized, placebo-controlled study plans up to approximately 372 patients, with change in FVC at week 48 as the primary endpoint. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · Phase 2 · Recruiting · Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ATYR holds $48.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.4M/quarter from operations,
an estimated runway of 15.5 months at that rate (BioRadar estimate, not company guidance).
Share count 2,549,230 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ATYR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATYR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.